Synopsis
Recognise the anti-U1-RNP-associated overlap phenotype, avoid diagnosing from antibody alone, screen pulmonary vascular and interstitial lung disease proactively, and match treatment to the dominant organ while the phenotype evolves.
- MCTD is a clinical overlap syndrome associated with persistent high-titre anti-U1-RNP; the antibody alone, especially a low or isolated laboratory result, does not establish disease.
- Typical early features include Raynaud phenomenon, puffy hands, inflammatory polyarthritis, myalgia or myositis and later scleroderma, lupus, pulmonary or oesophageal manifestations.
- No universally accepted diagnostic criteria exist for routine care; specialist diagnosis integrates phenotype, anti-U1-RNP, exclusion of mimics and longitudinal evolution.
Key red flags
Exertional syncope, chest pain, falling DLCO, raised NT-proBNP or right-heart signs may indicate pulmonary arterial hypertension and requires rapid haemodynamic assessment.
Exertional syncope, chest pain, disproportionate DLCO fall, raised NT-proBNP or right-heart findings suggests PAH and warrants urgent evaluation.
Investigation priorities
Support the mixed phenotype and identify evidence for an evolving defined connective-tissue disease.
Management branches
Raynaud, puffy hands, arthritis, weakness or systemic findings accompany anti-U1-RNP.
- Map skin, capillaries, joints, strength, swallowing, heart, lungs, renal and neurological systems and document the temporal sequence.
- Confirm anti-U1-RNP and request only phenotype-directed lupus, scleroderma, myositis and APS tests with baseline blood, urine, PFT and cardiac screening.
Key medicines
HydroxychloroquineFor selected inflammatory skin or joint disease use 200–400 mg orally daily, not exceeding 5 mg/kg actual body weight/day, at the lowest effective dose.
Nifedipine modified releaseStart 30 mg orally once daily for Raynaud phenomenon and increase, commonly to 60 mg once daily, according to response and blood pressure.